In February 2026, the U.S. Court of Appeals for the Federal Circuit issued a precedential decision in REGENXBIO Inc. v. Sarepta Therapeutics, ...

The most dominant, divisive issue in patent law over the last decade—Section101-eligibility and the Supreme Court’s Mayo-Alice framework—appears to have just become more divisive. Indeed, at least ...

On November 5, 2025, the USPTO hosted an informative “USPTO Hour” in which panelists discussed updates to Subject Matter Eligibility under 35 U.S.C. § 101 (“Section 101”). Speakers, including Charles ...

Counsel explain why Section 101 hurdles can make prosecution more expensive, and how they help clients avoid these extra costs It may not come as much surprise that the state of subject matter ...

A year on the from the Alice decision, many IP practitioners feel that Section 101 is in a state of ruin. Speakers at the BIO International Convention put forward proposals for Congress to overhaul ...